Safety of crizotinib in 892 Japanese ALK-positive advanced NSCLC patients: Interim report of post-marketing surveillance

被引：0
作者：
Okamoto, Isamu [1 ]
Nakagawa, Kazuhiko [2 ]
Ohe, Yuichiro [3 ]
Ueno, Naomi [4 ]
Banno, Shigeo [4 ]
Endo, Yutaka [4 ]
Ohki, Emiko [4 ]
Gemma, Akihiko [5 ]
机构：
[1] Kyusyu Univ Hosp, Ctr Clin & Transrat Res, Fukuoka, Japan
[2] Kinki Univ, Fac Med, Dept Med Oncol, Osaka, Japan
[3] Natl Canc Ctr, Dept Resp Med, Tokyo, Japan
[4] Pfizer Japan Inc, Tokyo, Japan
[5] Nippon Med Sch, Grad Sch Med, Dept Pulm Med & Oncol, Tokyo 113, Japan
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
SY12-3
引用
收藏
页码：37 / 37
页数：1
相关论文
共 50 条
[41]   Quality of Life for Crizotinib vs. Chemotherapy in Asian ALK-Positive NSCLC Patients [J].
Blackhall, Fiona ;
Mok, Tony ;
Nishio, Makoto ;
Kim, Dong-Wan ;
Wilner, Keith D. ;
Reisman, Arlene ;
Iyer, Shrividya ;
Solomon, Benjamin J. .
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) :S378-S379
[42]   Alectinib provides a new option for ALK-positive NSCLC patients after progression on crizotinib [J].
Abraham, Jame .
JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY, 2016, 14 (06) :241-243
[43]   The safety and effectiveness profile of eldecalcitol in a prospective, post-marketing observational study in Japanese patients with osteoporosis: interim report [J].
Saito, Hitoshi ;
Kakihata, Hiroyuki ;
Nishida, Yosuke ;
Yatomi, Sawako ;
Nihojima, Shigeru ;
Kobayashi, Yumiko ;
Tabata, Hidehiro ;
Nomura, Makoto .
JOURNAL OF BONE AND MINERAL METABOLISM, 2017, 35 (04) :456-463
[44]   Safety of baricitinib in Japanese patients with rheumatoid arthritis: the 2020 interim report from all-case post-marketing surveillance in clinical practice [J].
Fujii, T. ;
Atsumi, T. ;
Okamoto, N. ;
Takahashi, N. T. N. ;
Tamura, N. ;
Nakajima, A. ;
Matsuno, H. ;
Tsujimoto, N. ;
Nishikawa, A. ;
Ishii, T. ;
Takeuchi, T. ;
Kuwana, M. ;
Takagi, M. ;
Larsson, E. .
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2021, 50 :25-25
[45]   The safety and effectiveness profile of eldecalcitol in a prospective, post-marketing observational study in Japanese patients with osteoporosis: interim report [J].
Hitoshi Saito ;
Hiroyuki Kakihata ;
Yosuke Nishida ;
Sawako Yatomi ;
Shigeru Nihojima ;
Yumiko Kobayashi ;
Hidehiro Tabata ;
Makoto Nomura .
Journal of Bone and Mineral Metabolism, 2017, 35 :456-463
[46]   Interstitial Lung Disease Onset and Its Risk Factors in Japanese Patients With ALK-Positive NSCLC After Treatment With Crizotinib [J].
Gemma, Akihiko ;
Kusumoto, Masahiko ;
Kurihara, Yasuyuki ;
Masuda, Noriyuki ;
Banno, Shigeo ;
Endo, Yutaka ;
Houzawa, Hiroyuki ;
Ueno, Naomi ;
Ohki, Emiko ;
Yoshimura, Akinobu .
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (04) :672-682
[47]   Population modeling analyses of crizotinib in pediatric patients with ALK-positive advanced cancers [J].
Jerry, Li ;
Swan, Lin ;
Dana, Nickens ;
Balis, Frank M. ;
Greengard, Emily ;
Xu, Huiping .
PEDIATRIC BLOOD & CANCER, 2024, 71 (09)
[48]   24-week, Post-Marketing Surveillance Analysis of Upadacitinib in Japanese Patients with Rheumatoid Arthritis: The 2024 Interim Report [J].
Fujii, Takao ;
Okamoto, Nami ;
Abe, Asami ;
Takagi, Michiaki ;
Takahashi, Nobunori ;
Nakajima, Atsuo ;
Nakajima, Ayako ;
Nakayamada, Shingo ;
Nishida, Keiichiro ;
Kawaberi, Takeshi ;
Sunaga, Naomi ;
Tsujita, Yuki ;
Chonan, Sumi ;
Kuwana, Masataka ;
Tanaka, Yoshiya .
ARTHRITIS & RHEUMATOLOGY, 2024, 76 :1026-1029
[49]   Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment [J].
Bordi, Paola ;
Tiseo, Marcello ;
Rofi, Eleonora ;
Petrini, Iacopo ;
Restante, Giuliana ;
Danesi, Romano ;
Del Re, Marzia .
CLINICAL LUNG CANCER, 2017, 18 (06) :692-697
[50]   Post-marketing surveillance of erlotinib for NSCLC in Japan: Interim analyses of 3,488 patients (Pts) [J].
Ohe, Y. ;
Fukuoka, M. ;
Kudoh, S. ;
Nakagawa, K. ;
Johkoh, T. ;
Ando, M. ;
Yamazaki, N. ;
Takemoto, S. ;
Seki, A. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345